Anti-CD3e [Visilizumab (HuM291)]

Description:

Recombinant monoclonal antibody to CD3e. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma Visilizumab (HuM291).

Clone Name:

Visilizumab (HuM291)

Published Application(s):

immunesuppression, therapeutic, FC

Published Species Reactivity:

chimpanzee, Human

5

Products based on this clone:

{{heading}}

Please Select

Ab02390-23.0 Anti-CD3e [Visilizumab (HuM291)]
chimpanzee, Human
Rabbit IgG
Purified
In Stock

Ab02390-10.0 Anti-CD3e [Visilizumab (HuM291)]
chimpanzee, Human
Human IgG1
Purified
In Stock

Ab02390-10.3 Anti-CD3e [Visilizumab (HuM291)]
chimpanzee, Human
Human IgG1
Fc Silent™
Purified
Ships in 4-5 weeks

Ab02390-3.0 Anti-CD3e [Visilizumab (HuM291)]
chimpanzee, Human
Mouse IgG2b
Purified
Ships in 4-5 weeks

Ab02390-3.3 Anti-CD3e [Visilizumab (HuM291)]
chimpanzee, Human
Mouse IgG2b
Fc Silent™
Purified
Ships in 4-5 weeks

Loading...

UniProt Accession Number of Target Protein: P07766

Alternative Name(s) of Target: T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD3-ε
Immunogen: The original antibody was generated by immunizing BALB/c mice with activated human T cells as immunogens.

Specificity: This antibody recognises the human CD3 epsilon. This antibody also competes with OKT3 (Muromonab) for binding site on the human T cells suggesting that they bind overlapping or closely spaced epitopes.

Application Notes: This antibody is derived from its a murine parent antibody called M291. HuM291 was significantly less mitogenic to T cells in vitro as compared to OKT3 and induced the release of much lower levels of the cytokines tumor necrosis factor-α, interferon-γ, and interleukin-10. HuM291 still retained the ability to modulate the CD3 complex and inhibit the mixed lymphocyte reaction. This antibody competes with OKT3 for binding to human T cells, which was detected using flow cytometry (PMID: 10480417). In vitro studies using chimpanzee peripheral blood mononuclear cells (PBMCs), HuM291 was reported to be less mitogenic than OKT3 and effectively depleted peripheral T cells without eliciting clinical signs of cytokine release syndrome, and recovered T cells were functionally normal (PMID: 10480415). Phase 1 trial of HuM291 in patients receiving renal allografts suggested that it was well tolerated and rapidly depleted circulating T cells in a dose-dependent manner and was associated with only mild to moderate symptoms of cytokine release (PMID: 11152101). Treatment with visilizumab (HuM291) in severe steroid-refractory ulcerative colitis induced symptomatic response and clinical response (PMID: 19714757). The (99m)Tc labeled version of this antibody is also recommended for imaging of human T cells and study of human T-lymphocyte trafficking and lymphocytic infiltration of tissues and organs (PMID: 19759100). This antibody is also reported to have some activity in advanced glucocorticoid-refractory acute graft-versus-host disease (GVHD) (PMID: 11929757).

Antibody first published in: Cole et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation. (1999); 68(4):563-71. PMID:10480417
Note on publication: Describes the generation, characterization and comparison o f this antibody to another anti-CD3e antibody OKT3.